QPCT (glutaminyl-peptide cyclotransferase) is bound to HRAS and improves the stability of HRAS by inhibiting its ubiquitination degradation, which can activate the ERK signaling pathway and lead to sunitinib resistance in renal cell cancer[32]. The gene discussed is HRAS; the disease is renal cell adenocarcinoma.